Revenue
$4.29B
Gross Margin
+80.9%
Operating Margin
+17.5%
Net Margin
+13.5%
Income statement waterfall for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026
Net income: $577.22M
Margin breakdown for Alnylam Pharmaceuticals (ALNY) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $4.29B | $4.29B |
| Cost of Revenue | −$819.03M | $3.47B |
| Gross Profit | $3.47B | $3.47B |
| Operating Expenses | −$2.72B | $752.14M |
| Operating Income | $752.14M | $752.14M |
| Other Income / Expense | −$165.74M | $586.40M |
| Pre-tax Income | $586.40M | $586.40M |
| Tax Benefit | $22.14M | $608.54M |
| Other Items | −$31.32M | $577.22M |
| Net Income | $577.22M | $577.22M |
- Revenue$4.29B
- Cost of Revenue−$819.03M
- Gross Profit$3.47B
- Operating Expenses−$2.72B
- Operating Income$752.14M
- Other Income / Expense−$165.74M
- Pre-tax Income$586.40M
- Tax Benefit$22.14M
- Other Items−$31.32M
- Net Income$577.22M
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Cash Flow
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement